New Drug Development addresses the urgent global crisis of antimicrobial resistance, where common infections are becoming increasingly difficult to treat. It explores innovative strategies for developing new drugs and optimizing existing antimicrobial agents to combat drug-resistant bacteria, viruses, fungi, and parasites.
The book highlights the innovation gap in antimicrobial development, while also pointing out that some novel therapeutics like phage therapy and CRISPR antimicrobials show promise. It emphasizes the need for a multi-pronged approach, combining new drug discovery with responsible antimicrobial use, to maintain global health security.
The book's approach involves a balanced assessment of the scientific, clinical, and policy dimensions of antimicrobial resistance. It is structured into three key sections, beginning with the fundamental principles of antimicrobial action and resistance mechanisms.
It then explores the development of novel antimicrobial agents, including screening methods and clinical evaluation strategies. Finally, it focuses on optimizing current antimicrobial use through combination therapy and stewardship programs.
This book offers a unique perspective by integrating cutting-edge science with practical considerations for policy implementation. It serves as a valuable resource for researchers, clinicians, pharmaceutical scientists, policymakers, and students in medicine, microbiology, and public health, providing insights into the complexities of antimicrobial resistance and the challenges of developing new therapeutic strategies.
